Clinical Trial: NCT04267848
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Status:
RECRUITINGPhase:
Phase 3| Lead Sponsor: | National Cancer Institute (NCI) |
| Information Provided By: | National Cancer Institute (NCI) |
| Last Update Posted: | 2026-10-20 |
Study Overview
Brief Summary
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Official Title
Conditions
Intervention / Treatment
- Procedure: Biospecimen Collection
- Drug: Carboplatin
- Drug: Cisplatin
- Procedure: Computed Tomography
- Procedure: Echocardiography Test
- Drug: Gemcitabine Hydrochloride
- Procedure: Magnetic Resonance Imaging
- Other: Observation Activity
- Drug: Paclitaxel
- Biological: Pembrolizumab
- Drug: Pemetrexed Disodium
- Other: Questionnaire Administration
Other Study ID Numbers
- NCI-2020-00751
- NCI-2020-00751
- A081801
- A081801
- U10CA180821
Start Date (Actual)
Primary Completion Date (Estimated)
Study Completion Date (Estimated)
Enrollment (Estimated)
Study Type
Phase
| Lead Sponsor: | National Cancer Institute (NCI) |
| Information Provided By: | National Cancer Institute (NCI) |
| Last Update Posted: | 2026-10-20 |
Study Overview
Brief Summary
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Official Title
Conditions
Intervention / Treatment
- Procedure: Biospecimen Collection
- Drug: Carboplatin
- Drug: Cisplatin
- Procedure: Computed Tomography
- Procedure: Echocardiography Test
- Drug: Gemcitabine Hydrochloride
- Procedure: Magnetic Resonance Imaging
- Other: Observation Activity
- Drug: Paclitaxel
- Biological: Pembrolizumab
- Drug: Pemetrexed Disodium
- Other: Questionnaire Administration
Other Study ID Numbers
- NCI-2020-00751
- NCI-2020-00751
- A081801
- A081801
- U10CA180821